Impact News +++ Sensient targets high-single to double-digit 2026 local-currency growth while lifting Color Group outlook... (SeekingAlpha) +++ SENSIENT Aktie +8,81%

Dividenden News zur FORTRESS BIOTECH PRF Aktie

>FORTRESS BIO Performance

1 Woche: +4,6%

1 Monat: +3,6%

3 Monate: +15,2%

6 Monate: +100,0%

1 Jahr: +153,3%

laufendes Jahr: +53,0%

>FORTRESS BIOTECH PRF Aktie

Name:

FORTRESS BIOTECH.PRF.A 25

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US34960Q2084 / A2PYCP

Symbol/ Ticker:

CNB0 (Frankfurt) / FBIOP (NASDAQ)

Kürzel:

FRA:CNB0, ETR:CNB0, CNB0:GR, NASDAQ:FBIOP

Index:

Webseite:

https://www.fortressbiote..

Profil:

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
>einklappen..

Marktkapitalisierung:

61.27 Mio. EUR

Unternehmenswert:

61.39 Mio. EUR

Umsatz:

53.97 Mio. EUR

EBITDA:

-54.42 Mio. EUR

Nettogewinn:

5.81 Mio. EUR

Gewinn je Aktie:

-0.04 EUR

Schulden:

57.34 Mio. EUR

Liquide Mittel:

67.72 Mio. EUR

Operativer Cashflow:

-60.86 Mio. EUR

Bargeldquote:

1.6

Umsatzwachstum:

9.69%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

14.06.24 - 0.16757856€
14.05.24 - 0.16757768€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

FORTRESS BIOTECH PRF, FORTRESS BIOTECH, FORTRESS BIO

Letzte Datenerhebung:

25.04.26

>FORTRESS BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 32.2 Mio. St.

Frei handelbar: 76.64%

Leerverk. Aktien: -

Rückkaufquote: -117.48%

Mitarbeiter: 78

Umsatz/Mitarb.: 0.69 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 6.65

KBV: 8.96

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 59.56%

Gewinnmarge: 10.77%

Operative Marge: -111.27%

Managementeffizenz:

Gesamtkaprendite: 4.13%

Eigenkaprendite: 18.77%

>FORTRESS BIO Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Antikörper- Behandlung, Hauterkrankungen & -behandlung/ Dermatologie, Medizinprodukte & -technik/ Implantate/ Wundpflege
>Alle Branchen..

>FORTRESS BIO Chart & Kurs - NASDAQ

>FORTRESS BIO Dividenden News

Es sind leider keine News bekannt...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Frauen sprechen lieber als Männer. Trotzdem sind sie die schlechteren Redner, weil sie keinen Sinn für Demagogie haben. - Dame Edith Sitwell

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram